New cocktail aims to outsmart resistant tumors
NCT ID NCT05383482
First seen Nov 17, 2025 · Last updated Jun 19, 2026 · Updated 26 times
Summary
This early-stage trial tested a combination of three drugs—afuresertib, sintilimab, and chemotherapy—in 22 adults with solid tumors (like lung, cervical, or stomach cancer) that had stopped responding to prior immunotherapy. The goal was to find a safe dose and see if the combo could shrink tumors. Results are still being analyzed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Chongqing Cancer Hospital
Chongqing, Chengdu, China
-
Jilin Cancer Hospital
Changchun, Jilin, China
-
West China Second University Hosital, Sichuan University
Chengdu, Sichuan, China
-
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
afuresertib (a targeted drug) combined with sintilimab (an immunotherapy) and chemotherapy (nab-paclitaxel or docetaxel)
What this could lead to
If successful, this combination could offer a new treatment option for people with certain cancers that have stopped responding to standard immunotherapy.
What could go wrong
This is an early-phase trial with only 22 participants, so results may not apply broadly. The combination also carries risks of side effects from multiple drugs.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.